The majority of female ob/gyns believe menstrual suppression is safe when used long-term (69%) or occasionally (30%). More than half (53%) say they've used oral contraceptives to suppress their own menstruation.
Among those female ob/gyns who said they had undergone a caesarean delivery, 78% said it was performed for medical reasonsnot as an elective. When asked if they would perform an elective C/S if a patient requested one, 36% said they would not, 32% said they would, and another 28% said it would depend on the circumstances.
Female ob/gyns are more likely than American women in general to be screened for cervical or breast cancer. While 89% of American women of reproductive age have had a Pap test within the past 3 years, 78% of female ob-gyns had the test within the past 18 months and 90% had one within the past 2 years. Additionally, 70% of American women over age 40 in 2002 had a mammogram in the previous 2 years, while 73% of female ob/gyns age 48 and over had one in the past year and 86% had one within the past 2 years.
50% of female ob/gyns use hormone therapy to treat their own menopausal symptoms, and 19% said they did not use any treatment. Other types of treatment used by female ob/gyns include antidepressants (13%) to treat hot flashes and alternative natural therapies (13%), such as botanical black cohosh.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, walk through real-world dosing, cost workarounds, and the labs that actually matter for safety and efficacy.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, reframe testosterone candidacy around clinical presentation and hormone state, not age cutoffs or a single number on a chart.
Before prescribing testosterone, know what the evidence actually proves. Maria Uloko, MD, draws a sharp line between the one population the data supports and the much wider group of women asking about it.
David Shalowitz, MD, MSHP, emphasizes spreading awareness of opportunistic salpingectomy across specialties while grounding its use in shared decision-making.